Aimmed’s Insomnia App Approved As Korea’s First Digital Therapeutic
But Reimbursement Decision May Take Time
More approvals of digital therapeutics are expected to come in the wake of South Korea's first approval of this type of product, Aimmed’s insomnia mobile app Somzz. But reimbursement decisions on such therapies could take months and will be closely monitored going forward.
You may also be interested in...
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.